OpGen Inc

NASDAQ:OPGNUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.

Contact Information

Headquarters

9717 Key West Avenue, Suite 100ROCKVILLE, MD, United States 20850

Phone

301-869-9683

Fax

301-869-9684

Executives

Independent Chairman of the Board

William Rhodes

Chief Executive Officer, Director

Oliver Schacht

Chief Financial Officer, Corporate Secretary

Albert Weber

Chief Operating Officer

Johannes Bacher

Independent Director

Mario Crovetto